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Abstract
The rare human disorder chorea-acanthocytosis (ChAc) is caused by mutations in hVPS13A gene. The hVps13A protein inter-
acts with actin and regulates the level of phosphatidylinositol 4-phosphate (PI4P) in the membranes of neuronal cells. Yeast
Vps13 is involved in vacuolar protein transport and, like hVps13A, participates in PI4P metabolism. Vps13 proteins are con-
served in eukaryotes, but their molecular function remains unknown. One of the mutations found in ChAc patients causes
amino acids substitution I2771R which affects the localization of hVps13A in skeletal muscles. To dissect the mechanism of
pathogenesis of I2771R, we created and analyzed a yeast strain carrying the equivalent mutation. Here we show that in yeast,
substitution I2749R causes dysfunction of Vps13 protein in endocytosis and vacuolar transport, although the level of the pro-
tein is not affected, suggesting loss of function. We also show that Vps13, like hVps13A, influences actin cytoskeleton organ-
ization and binds actin in immunoprecipitation experiments. Vps13-I2749R binds actin, but does not function in the actin
cytoskeleton organization. Moreover, we show that Vps13 binds phospholipids, especially phosphatidylinositol 3-phosphate
(PI3P), via its SHR_BD and APT1 domains. Substitution I2749R attenuates this ability. Finally, the localization of Vps13-GFP is
altered when cellular levels of PI3P are decreased indicating its trafficking within the endosomal membrane system. These re-
sults suggest that PI3P regulates the functioning of Vps13, both in protein trafficking and actin cytoskeleton organization.
Attenuation of PI3P-binding ability in the mutant hVps13A protein may be one of the reasons for its mislocalization and dis-
rupted function in cells of patients suffering from ChAc.
Introduction
The Vps13 proteins are conserved in all eukaryotic organisms.
In the human genome, Vps13 proteins are encoded by four
genes VPS13A, VPS13B, VPS13C and VPS13D (1). For clarity
VPS13A is further referred to as hVPS13A. Mutations in hVPS13A
coding for the hVps13A protein, also named chorein, are the
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cause of a rare autosomal disorder, chorea-acanthocytosis
(ChAc; OMIM 200150) (2), characterized by adult-onset chorea,
progressive neurodegeneration and abnormal erythrocyte
morphology - acanthocytosis. Most mutations found in ChAc
patients lead to the generation of a premature stop codon and
therefore cause a marked reduction of the mutant protein level
in cells probably due a premature termination of translation
and degradation of the hVPS13A transcript via nonsense medi-
ated decay (3). However, several missense mutations have also
been described. One of them, causes amino acid (aa) substitu-
tion I2771R and affects the localization of the hVps13A in skel-
etal muscles (4). The hVps13A is apparently involved in actin
cytoskeleton organization and dynamics, since red blood cells
and platelets from ChAc patients display depolymerization of
the cortical actin cytoskeleton probably causing the acanthocy-
tosis (5,6). Moreover an interaction between hVps13A and
b-actin has been shown (7). The hVps13A protein, plays a role in
metabolism of phospholipids, as it was shown that knockout of
human hVPS13A led to a reduction in the level of phosphatidyli-
nositol 4-phosphate (PI4P) in the Golgi apparatus and plasma
membrane in the neuronal model PC12 cells (8). However, the
molecular function of hVps13A is still unknown.
In the yeast Saccharomyces cerevisiae, which is a unicellular
model eukaryotic organism, the single VPS13 (YLL040C) gene
codes for a protein which is involved in the transport of proteins
from the Golgi apparatus to the vacuole, as documented by mis-
localization of carboxypeptidase Y (CPY) (9–11), in the endocytic
transport of lipid membranes from the plasma membrane to
the vacuole, as was shown using FM4-64 lipophylic dye (12) and
also in sporulation of diploids (11,13). Vps13 was localized in
endosomes and prospore membrane (13,14). Vps13, like
hVps13A, may also play a role in the regulation of the actin
cytoskeleton and phospholipid metabolism, since it was cap-
tured in an in vitro actin assembly assay using microbeads
coated with Las17, an activator of actin nucleation complex (15).
In addition, the prospore membrane from vps13D strain has
reduced phosphatidic acid (PA), PI4P and phosphatidylinositol
4,5-bisphosphate (PI(4,5)P2) content (13). Similarities in pheno-
types caused by Vps13 protein dysfunction in cells from pa-
tients and in yeast make this organism a good model to study
the effects of human Vps13A mutations on cellular functions.
The fact that Vps13 proteins influence the level of phospho-
derivatives of phosphatidylinositol (PIPs) suggests that this de-
fect might be the main problem in patients. It is well
documented that PIPs are not only structural components of
the lipid bilayers but also a key regulators of many cellular proc-
esses in eukaryotes including vesicular transport, cell prolifer-
ation, and actin cytoskeleton organization (16). Different
phosphoinositide species are located in a specific cellular com-
partments and, hence, contribute to membrane identity (17).
PIPs also serve as specific membrane-anchored determinants
for the recruitment of a wide range of proteins, which can inter-
act with these lipids via different conserved modular binding
motifs. For example, PI4P, which is synthesized in yeast cells at
the Golgi apparatus and at the plasma membrane, functions in
multiple membrane trafficking pathways. PI4P production at
the Golgi has a crucial role in maintaining secretory protein ex-
port to the cell surface, trafficking of cargoes to the vacuole, and
in endocytic protein transport (18–20). The PI4P synthesized at
the plasma membrane is implicated in regulation of endocytic
trafficking mostly by regulation of actin cytoskeleton organiza-
tion (21) and is a substrate for the synthesis of PI(4,5)P2 which
regulates endocytosis, exocytosis, cytokinesis, maintenance of
cell polarity, and actin cytoskeleton organization. PI(4,5)P2
functions not only as a localization determinant but also some
effectors rely on PI(4,5)P2 binding to regulate their activities dir-
ectly. For example, it accelerates the formation of actin net-
works during endocytic vesicle budding. More than 30 actin
filament-binding proteins have been reported to associate dir-
ectly with phosphoinositides (22). In contrast to PI4P and
PI(4,5)P2, phosphatidylinositol 3-phosphate (PI3P) is located pre-
dominantly at the endosomal membrane, where it recruits dif-
ferent proteins, usually sharing a small subset of domains that
interact directly with PI3P (17,23–25). The best characterized
PI3P-binding domains are FYVE and PX (26). Two complexes:
endosomal sorting complexes required for transport (ESCRTs)
(25) and retromer complex (24) are examples of complexes re-
cruited to endosomes based on PI3P binding. ESCRT complexes
are required for the formation of the multivesicular body (also
called late endosome), a crucial step in the delivery of cargo des-
tined for degradation in the vacuole (27), while retromer com-
plex is required for endosome-to-Golgi retrograde transport and
recycling of proteins from the endosome to the plasma mem-
brane (24). PI3P is also enriched in preautophagosomal structure
and the isolation membrane, and is required for localization of
Atg18-Atg2 complex of core autophagy proteins to these struc-
tures (28,29). Atg18 b-propeller protein binds PI3P via an FRRG
motif (30,31) and Atg2 was recently found to contain an APT1
domain with the ability to bind PI3P independently of Atg18
(32). Atg2 proteins show some homology to Vps13 proteins (1)
and therefore may play similar molecular functions in different
processes.
To shed more light on how the I2771R substitution found in
ChAc patient affects hVps13A, we constructed a yeast strain
producing Vps13 with an equivalent substitution, vps13-I2749R,
and studied its effects on protein trafficking. We tested the in-
volvement of wild type and mutant versions of Vps13 in actin
cytoskeleton organization and their ability to bind actin and lip-
ids, and we discovered that Vps13 specifically binds PI3P while
in Vps13-I2749R this binding is compromised. Additionally, the
Vps13-I2749R-GFP was mislocalized in cells with decreased level
of PI3P. Our results suggest that functioning of Vps13 is regu-
lated by its interaction with PI3P, and losing PI3P-binding ability
by hVps13-I2749R mutant protein accompanied with its abnor-
mal cellular cycling might be a reason for its pathogenicity in
some patients suffering for ChAc.
Results
Vps13-I2749R mutation, an equivalent of human
mutation I2771R found in patient suffering from ChAc,
impairs the function of the yeast Vps13 protein
Yeasts are widely used as a model organism to study human
proteins and to improve the understanding of diverse human
diseases (33–35). We therefore used the yeast cell system to
study hVps13A function. First, we tested the ability of human
hVPS13A to complement the defects of vps13D cells. The splice
variant 1 of hVPS13A was used in this study as it is the most
abundant one (1). The vps13D strain was transformed with sin-
gle copy plasmids bearing hVPS13A or hVPS13A-GFP under the
transcriptional control of three constitutive promoters of
increasing strength: ADH1, TEF1, and GPD (TDH3) (36) and with
plasmid bearing yeast VPS13 with native promoter. To check
the functionality of the human protein, complementation of the
most characteristic phenotype of vps13D – missorting of CPY –
was tested. CPY is a native vacuolar peptidase, but in vps13D
mutant it is secreted from cells (12). Yeast cells were grown on
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nitrocellulose membrane on an SC-leu plate, washed out from
the membrane surface and the secreted CPY was detected by
western blotting using anti-CPY antibody. The vps13D strain
bearing hVPS13A still transported CPY outside the cells, at a
similar level as the vps13D control. This lack of complementa-
tion was independent of the strength of the promoter driving
expression of hVPS13A (Fig. 1A). We also checked complementa-
tion of the other vps13D phenotypes related to protein traffick-
ing: hypersensitivity to canavanine and degradation of the
Sna3-GFP protein. Yeast cells lacking VPS13 gene were more
sensitive to canavanine, the toxic analog of arginine, which
uses the same permease, Can1, to enter cells (Fig. 1B), indicating
the defect of vps13D cells in Can1 endocytosis. Also the trans-
port and degradation in the vacuole of the Sna3-GFP, an adapter
protein involved in multivesicular body sorting of proteins and
transport to the vacuole (37), is disturbed in this strain as as-
sessed by accumulation of Sna3-GFP and Sna3-GFP ubiquiti-
nated species and diminished ratio of the degradation product,
GFP (Fig. 1C). All vps13D phenotypes tested were fully comple-
mented by yeast VPS13 but in contrast, none of them of was
suppressed by the expression of the hVPS13A gene or hVPS13-
GFP fusion (Fig. 1A, B and C). In other control experiments, we
used plasmids bearing the VPS13-GFP gene under the control
of ADH1, TEF1 and GPD promoters and all these plasmids sup-
pressed the abnormal secretion of CPY and restored growth
of vps13D strain on canavanine-containing medium
(Supplementary Material, Fig. S1A and B). To find the reason for
the lack of vps13D complementation, the cellular levels of
hVps13A and yeast Vps13 proteins C-terminally tagged with
GFP were compared using anti-GFP antibody. The hVps13A-GFP
was not detectable in total cell extracts (not shown) but was
observed in immunoprecipitates after using magnetic beads
coated with anti-GFP antibody, indicating that the level of
human protein in yeast is extremely low (Fig. 1D). This shows
that hVPS13A-GFP, and possibly also untagged hVPS13, may be
poorly expressed or be unstable and that may be a reason for
lack of complementation of vps13D defects.
Thus, we introduced the human mutation found in ChAc pa-
tient in the yeast VPS13 gene and tested the mutant for comple-
mentation of vps13D defects. The amino acid sequence of
hVps13A (UniProtKB ID: Q96RL7-1) was compared with that of
yeast Vps13 (SGD ID: S000003963) using the Clustal Omega tool
(EMBL-EBI). We found that the I2771R substitution in ChAc pa-
tients (4) is present in the evolutionary conserved region of
hVps13A and our multiple sequence analyses show that the
hydrophobic nature of this position is conserved in all species
tested (Fig. 2A). A mutation causing equivalent substitution,
I2749R, was introduced into yeast VPS13 gene under its native
promoter and the ability to complement the vps13D defects was
tested. In contrast to wild type VPS13 gene the vps13-I2749R al-
lele was unable to suppress vps13D defects, such as canavanine
hypersensitivity, secretion of CPY and delay in Sna3-GFP
degradation (Fig. 2B, C and D). This vps13-I2749R allele did not
influence the wild type strain growth, canavanine sensitivity,
Figure 1. Human hVPS13A expressed in yeast cells does not complement vps13D defects. (A) Secretion of CPY. Yeast cultures were spotted on nitrocellulose membrane
plated on SC-leu medium, incubated for 14-16 h and washed off. The level of secreted CPY was estimated using anti-CPY antibody. (B) Sensitivity of yeast strains to
L-canavanine. Serial dilutions of wild type and vps13D strains bearing indicated plasmids were spotted on synthetic minimal medium supplemented with (3 mg ml 1)
or without L-canavanine. (C) Degradation of Sna3-GFP protein. Cells as in B were grown in SC-leu-ura medium to log-phase and total protein extracts were analyzed by
SDS-PAGE followed by Sna3-GFP and GFP detection with anti-GFP antibody. Ubiquitinated (Ub) Sna3-GFP derivatives are indicated. The ratio GFP/(Sna3-GFPþSna3-
GFP-UbþGFP) was calculated and is given for each strain as percentage of free GFP. (D) The detection of the hVps13A protein in yeast cells. Proteins extracted from
vps13D strain expressing VPS13-GFP or hVPS13A-GFP under the TEF1 promoter were immunoprecipitated, subjected to SDS-PAGE and western blot analysis with anti-
GFP antibody.
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Sna3-GFP degradation and CPY sorting indicating that mutation
is recessive. To test if lack of complementation could be a result
of decreased level of the mutant protein, western blot analysis
of cell extracts derived from vps13D expressing wild type or mu-
tant PTEF1-VPS13-GFP was performed. The level of mutant
Vps13-I2749R-GFP protein was similar to wild type Vps13-GFP
protein (Fig. 2E), showing that the reason for the non-
functionality of the I2749R substitution is not due to a signifi-
cant reduction in its level.
Vps13-I2749R expressing cells have aberrant actin
cytoskeleton organization
Because of the protein transport defects and the unaffected
level of Vps13-I2749R protein, we aimed to determine the rea-
son for the loss of function phenotype of mutant expressing
cells. It was shown previously that hVps13A is involved in actin
cytoskeleton organization, since red blood cells and platelets
from ChAc patients display depolymerization of the cortical
actin cytoskeleton (5,6), and that hVps13A interacts with b-actin
(7). Moreover, the yeast Vps13 protein was found among the
components of Las17 activator-derived actin patch cortical net-
work in vitro (15). The actin cytoskeleton is important for provid-
ing the forces required for a variety of cellular processes based
on membrane dynamics, like endocytosis, exocytosis, and ves-
icular trafficking at the Golgi apparatus (38–40). Thus, we
hypothesized that Vps13 plays a role in actin cytoskeleton or-
ganization also in yeast and that vps13-I2749R mutation might
affect the interaction with actin network. To test this, staining
of actin filaments using fluorescently labeled phalloidin was
performed and the organization of the actin cytoskeleton in
yeast vps13D cells was observed by fluorescence microscopy. In
a wild type strain about 90% of dividing cells showed a well-
organized actin cytoskeleton, the actin patches were concen-
trated in the bud and bud neck and actin cables were formed
along the bud-mother cell axis, while in the vps13D mutant only
about 50% of dividing cells exhibited normal polarization of the
actin cytoskeleton. Among the cells with an abnormal actin
cytoskeleton were those cells with more than five actin patches
in the mother cell and with actin clumps in the central or distal
part of the mother cell (Fig. 3A). Thus, Vps13 is involved in actin
cytoskeleton organization in yeast as hVps13A is in human
cells. Therefore, the organization of actin cytoskeleton in
vps13D strain expressing vps13-I2749R from the plasmid was
tested. VPS13 and PTEF1-VPS13-GFP complemented fully the actin
cytoskeleton defect of vps13D while vps13-I2749R expressing
cells were still defective (Fig. 3B and C and Supplementary
Material, Fig. S1). This result indicates that Vps13 is required for
the normal organization of the actin cytoskeleton in yeast and
the Vps13-I3749R is deficient also in this aspect of Vps13
functioning.
To further investigate the role of yeast Vps13 in actin cyto-
skeleton, the interaction between Vps13 and actin was tested.
Vps13-GFP was immunoprecipitated from the total cell extracts
of vps13D cells transformed with the plasmid bearing
PTEF1-VPS13-GFP and the copurified proteins were analyzed for
the presence of actin by western blotting. Indeed, actin was
clearly visible in the immunoprecipitate, indicating that Vps13-
GFP forms a complex with actin, directly or indirectly (Fig. 3D).
Because the mutant vps13-I2749R-GFP failed to rescue all
observed actin cytoskeleton and protein transport defects of
vps13D, we asked if it was due to a loss of the Vps13 ability
to interact with actin. To answer this question, the vps13D
strain expressing vps13-I2749R-GFP was used for co-
immunoprecipitation. Surprisingly, actin was present in the
Vps13-I2749R immunoprecipitate similarly as for Vps13-GFP
(Fig. 3D), indicating that the I2749R substitution does not com-
promise the interaction of Vps13 with actin but affects the actin
cytoskeleton another way.
Vps13 binds PI3P and I2749R substitution attenuates
this interaction
Because the interaction of Vps13 protein with actin is not af-
fected by the I2749R substitution, we analyzed the structural or-
ganization of Vps13 to identify putative motifs that may bind
other factors important for functioning of Vps13. The Vps13
protein contains two well-defined domains (Conserved
Domains database, CDD NCBI): the N-terminal Chorein_N do-
main, which is proposed to form a leucine zipper for oligomer-
ization or protein-protein interactions (41); and the SHR_BD
(SHR-binding domain; previously known as DUF1162). SHR_BD
is present in SHRUBBY (At5g24740), a vacuolar sorting protein of
A. thaliana (42). The I2749R amino acid substitution was located
in the region which was not previously characterized. Our bio-
informatics analysis using the HHpred program (43; http://tool
kit.lmb.uni-muenchen.de/hhpred; date last accessed February
8, 2017) additionally identified Vps13 region similar to the APT1
domain (Probab¼ 99.68%, E-value¼ 5.9e-15, Score¼ 141.23;
PF10351, aa 2575-2832) (Supplementary Material, Fig. S2) and
two ATG_C (Autophagy-related protein C terminal domain) do-
mains – one full-length (aa 2921-3005) and one truncated (aa
2845-2909) (Fig. 4A). These domains (APT1, aa 2522-2856 and
ATG_C, aa 2871-3036) were also found in hVps13A (Fig. 4A). The
APT1 domain was first described in the Golgi apparatus protein
APT1 of maize, involved in the growth of pollen tubes (44). We
have recently found that APT1 domain is also present in yeast
Atg2, a core autophagy protein, and we also show that APT1 of
Atg2 binds PI3P (32). Since the I2749R substitution is located in
the distal part of the putative APT1 domain of Vps13 (Fig. 4A),
we speculated that APT1 of Vps13 can possibly also bind lipids
and that this substitution may affect the lipid-binding ability.
Since our analysis indicated that SHR_BD and APT1 may also be
distantly related domains, we included SHR_BD in further
analysis.
To test for lipid interaction, Vps13 fragments, containing the
APT1, SHR_BD or both these domains (Fig. 4A) fused with a GST
tag at the N terminus, were produced in E. coli. Purified proteins
were incubated with commercial PIP strips and the lipid-bound
proteins were detected using anti-GST antibody. All three Vps13
fragments were able to interact with lipids, but with different
specificity. SHR_BD-APT1 and APT1 domain alone bound almost
exclusively PI3P and the binding was stronger for the longer
fragment (Fig. 4B). The fragment containing the SHR_BD domain
alone interacted equally well with all phosphoinositides and
also with phosphatidic acid and lysophosphatidic acid (Fig. 4B).
Although the PIP strip assay is qualitative rather than quantita-
tive, the obtained results suggest that the SHR_BD domain is re-
sponsible for non-specific phospholipid binding while the APT1
domains confers specificity on this interaction.
To compare lipid binding ability of wild type SHR_BD-APT1
fragment of Vps13 with its mutant version containing I2749R
substitution, the liposome pull-down method was used. Total
bacterial extracts containing GST-Vps13-(SHR_BD-APT1), GST-
Vps13-I2749R-(SHR_BD-APT1) or GST-Fab1-(FYVE), a control fu-
sion containing PI3P-binding domain of yeast PI3P 5-kinase
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Figure 2. Yeast VPS13 gene bearing the ChAc mutation I2749R does not complement deletion of VPS13 in yeast cells. (A) The homology of Vps13 region containing the
ChAc mutation (I2771R in human and I2749R in yeast). Logo diagram showing sequence conservation of the Vps13 orthologs from 15 model organisms was obtained
using the WebLogo 3 program (67). Alignment was prepared using Clustal Omega tool (EMBL-EBI). (B) Secretion of CPY. Yeast cultures expressing wild type and mutant
VPS13 under control of VPS13 native promoter were grown and analyzed as in Figure 1A. (C) Sensitivity of cells to L-canavanine. Serial dilutions of wild type and vps13D
strains bearing plasmids containing wild type and mutant VPS13 under the control of VPS13 native promoter were spotted on medium supplemented with (1 mg ml 1)
or without L-canavanine. (D) Degradation of Sna3-GFP protein. Cells expressing PVPS13-VPS13 or PVPS13-vps13-I2749R were grown in SC-leu-ura medium to log-phase and
total protein extracts were analyzed by SDS-PAGE followed by Sna3-GFP detection with anti-GFP antibody. Irrelevant lane was removed. Percentage of free GFP [GFP/
(Sna3-GFPþSna3-GFP-UbþGFP)] in each lane is given. (E) The level of Vps13-I2749R-GFP in yeast cells. Cells transformed with plasmids bearing PTEF1-VPS13-GFP or
PTEF1-vps13-I2749R-GFP were grown to log-phase, total protein extracts were prepared and analyzed by SDS-PAGE followed by anti-GFP western blotting.
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Fab1 (45), were incubated with liposomes containing PI or PI3P.
We observed that similarly to control GST-Fab1-(FYVE) protein,
the wild type fragment of Vps13 was dominantly associated
with PI3P-containing liposomes compared to PI-containing
liposomes (Fig. 4C), (4.2% PI; 7% PI3P and 2.7% PI; 10% PI3P, re-
spectively). Mutant Vps13 fragment associated more efficiently
with PI and less efficiently with PI3P (4.5% PI; 5.4% PI3P) when
compared to wild type fragment. These results suggest
Figure 3. Vps13 influences the actin cytoskeleton organization and interacts with actin. (A) Organization of actin cytoskeleton in vps13D cells. Wild type and vps13D
cells were grown to log-phase, fixed and stained using labeled phalloidine and observed by fluorescence microscopy. Scale bar, 5 mm. (B). Actin cytoskeleton organiza-
tion in vps13D cells bearing PVPS13-vps13-I2749R. Assay was performed as in A. (C) Graphic representation of actin cytoskeleton organization in vps13D cells. At least 100
cells of each strain were observed and the percentage of cells with well-polarized and non-polarized actin cytoskeleton is indicated. Error bars represents standard de-
viations for three experiments. (D) Immunoprecipitation of wild type and mutant Vps13-GFP proteins. Yeast cells expressing PTEF1-VPS13-GFP or PTEF1-VPS13-I2749R-GFP
were disrupted using glass beads and GFP-tagged proteins were precipitated using GFP-Trap magnetic beads. Samples were analyzed by standard SDS-PAGE
followed by western blotting using anti-GFP and anti-actin antibodies. The 1/100 volume of extract taken to IP was loaded in Total lanes. Strain bearing empty plasmid
or plasmid encoding GFP alone was used as a negative control. Irrelevant lane was removed.
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Figure 4. Vps13 fragments bind lipids and I2749R substitution attenuates this interaction. (A) Schematic representation of hVps13A and Vps13 domain structure and
fragments used in PIP strip assay. Coomassie stained gel showing purified fragments used for PIP strip assay is also shown. Position of isoleucine (I) residue mutated to
arginine (R) in ChAc patient and the corresponding site in yeast protein (I2771 in hVps13A and I2749 in yeast Vps13) is indicated by asterisks. Particular domains are
indicated by boxes: black, chorein_N; striped, SHR_BD; grey, APT1; dotted, truncated and full-lengh ATG_C. (B) Binding of Vps13 fragments to lipids. GST-Vps13-
(SHR_BD -APT1), GST-Vps13-(APT1), GST-Vps13-(SHR_BD) proteins were expressed in E. coli and purified. Up to 1 mg of purified proteins was used to test for binding to
lipids deposited on the membrane (PIP strip). The fusion proteins were detected using anti-GST antibody. LPA, lysophosphatidic acid; LPC, lysophosphocholine; PI,
phosphatidylinositol; PI3P, PI3-phosphate; PI4P, PI4-phosphate; PI5P, PI5-phosphate; PE, phosphatidylethanolamine; PC, phosphatidylcholine; S1P, sphingosine 1-phos-
phate; PI(3,4)P2, PI(3,4)-bisphosphate; PI(3,5)P2, PI(3,5)-bisphosphate; PI(4,5)P2, PI4,5-bisphosphate; PI(3,4,5)P3, PI(3,4,5)-trisphosphate; PA, phosphatidic acid; PS, phos-
phatidylserine. Experiment was performed at least two times with proteins from independent purifications. Representative result is shown. (C) Binding of Vps13
fragments to PI- and PI3P-containig liposomes. Crude extracts from E. coli containing wild type (WT) or I2749R mutant (*) variant of GST-Vps13-(SHR_BD -APT1) and
GST-Fab1-(FYVE) as a positive control were incubated with indicated biotin-tagged liposomes. Liposomes were pull down using the streptavidin-covered beads and
processes for western blot. All pull down fractions and 32ll of each supernatant were loaded on the gel. The fusion proteins were detected using anti-GST antibody.
Experiment was performed three times. Representative result is shown.
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lower-binding ability to PI3P of mutant Vps13 SHR_BD-APT1
when amino acid I2749 is substituted for R. These results sug-
gest further that the attenuation of Vps13 ability to bind PI3P
lipid is sufficient to compromise its functioning in both, actin
cytoskeleton organization and transport of CPY, Can1 and Sna3
proteins.
The binding of Vps13 to PI3P regulates its localization
Our results have indicated that binding to PI3P is important for
functioning of Vps13. PI3P, similar to other phosphoderivatives
of PI, is characteristic for some cellular compartments, such as
endosomes and autophagosomes, and can confer membrane
identity (17). It also recruits many proteins to its site of action,
thus determining their localization and functioning in cellular
processes. To determine whether PI3P influences the localiza-
tion of Vps13, strains devoid of individual subunits of PI3-
kinase expressing PTEF1-VPS13-GFP or PTEF1-vps13-I2749R-GFP
from the plasmid were used. There is only one PI3-kinase in
yeast which is the sole source of PI3P and phosphorylates only
PI. It is part of two distinct complexes which function in separ-
ate membrane trafficking processes. Complex I plays an essen-
tial role in autophagy and is composed of the catalytic dimer
Vps34-Vps15, and Vps30 and Atg14 subunits, while complex II
functions in endosomal retrograde protein sorting, multivesicu-
lar body protein sorting and Golgi to vacuole transport, and in-
stead of Atg14 contains Vps38 (17,46,47). In vps30D and vps38D
mutants the level of PI3P is decreased about threefold and endo-
somal retrograde transport is defective while in atg14D the PI3-
kinase complex I is not recruited to the phagophore assembly
site and only autophagy is compromised (24,46). In wild type
strains, Vps13-GFP was observed to be mainly diffuse in the
cytoplasm though in a small proportion of cells small dots were
observed, possibly endosomes. In contrast, in vps30D strain,
Vps13-GFP formed a dot adjacent to vacuole in 40% of cells and
this dot was very large in 10% of cells. This increased punctate
appearance of Vps13-GFP was similar in vps38D strain and was
absent in atg14D strain (Fig. 5A), thus it correlates with
decreased PI3P level. The observed large dots of Vps13-GFP were
located perivacuolarly and colocalized with the membrane
compartment stained by FM4-64 lipophylic dye which is taken
up to the cell by endocytosis (Fig. 5B), suggesting that Vps13-
GFP excessively accumulates on the surface of the membran-
eous structure of endocytic origin, likely endosome or multive-
sicular body, when the endosomal level of PI3P is low. To test
that prediction, Snf7-RFP, an ESCRT-3 protein, was used as a
marker of the multivesicular body/late endosome (14).
Surprisingly, Vps13-GFP and Snf7-RFP did not colocalize, they
accumulated in different perivacuolar spots in the cell (Fig. 5C)
and is not clear if Snf7-RFP is endosomal in vps30D mutant cells.
In contrast, Vps13-I2749R-GFP was found in small dots only in
10% of vps30D and vps38D cells and a large dot was not observed
in these cells (Fig. 5A) indicating that I2749R mutation prevents
endosomal accumulation of Vps13 or formation of this com-
partment in this condition. This Vps13-GFP endosomal localiza-
tion together with PI3P-binding ability support the idea that
Vps13 may cycle between cytoplasmic and endosomal localiza-
tion and this cycling, which depends on PI3P binding, is
required for endosomal sorting and actin cytoskeleton organ-
ization, and is compromised by I2749R substitution.
Discussion
Despite the fact that hVPS13A is involved in the human disease
chorea-acanthocytosis, little is known about its structure and
molecular function. Here, we attempted to broaden knowledge
about the role of Vps13 in cells and find how mutations can af-
fect its function in yeast. The present study describes the con-
struction and properties of the yeast strain producing mutant
Vps13 with changes equivalent to the I2771R substitution in
hVps13A found in ChAc patients. This replacement of the con-
served hydrophobic isoleucine residue by positively charged ar-
ginine within the putative APT1 domain is detrimental to
human cells, however how this pathogenic change affects
hVps13A remained unknown. Yeast Vps13 is similar to human
Vps13A, especially in the region of hVps13A modified by I2771R.
Isoleucine 2771 is conserved in yeast, human and 64% of Vps13
sequences analyzed and in other is substituted by similar aa,
leucine, suggesting that its pathogenic mutation to arginine
may similarly affect both the human and yeast proteins. Here,
we found new phenotypes of vps13D mutants and identified a
novel APT1 domain in Vps13 and hVps13A proteins in which
I2749/2771 is located, respectively. We also documented that
this APT1 domain along with the preceding SHR_BD domain to-
gether, and independently, bind phosphorylated phosphatidyl-
inositol lipids. Moreover, we show that I2749R substitution at-
tenuates lipid binding ability of SHR_BD-APT1 fragment of
Vps13 and results in Vps13 loss of function with an impact on
actin cytoskeleton organization and vesicular transport.
To broaden the knowledge on vps13D mutants, various
markers of vesicular traffic were tested and we found that cells
devoid of Vps13 are defective in endocytosis of Can1, and Golgi
to vacuole transport and degradation of Sna3-GFP. We included
these new phenotypes for further complementation analysis in
addition to the classical test for CPY secretion, the first vps13D
phenotype described (9–11). Our other finding that yeast vps13D
mutants show defects in actin cytoskeleton organization and
Vps13 is present with actin in immunoprecipitates similarly to
hVps13A, also adds further support to the use of yeast as a suit-
able model organism to study effects of hVps13A mutations.
The actin cytoskeleton is implicated in several vesicular trans-
port steps, such as plasma membrane endocytic invagination
and endosome movement (48–51), multivesicular body biogen-
esis (50,52) and retrograde transport (53) in yeast and mammals.
Various sets of proteins are involved in building actin filaments
networks in these different locations (54) and bridge actin cyto-
skeleton with membrane dynamics. Actin cytoskeleton defects
correlate well with vesicular transport defects in vps13D but we
could not discriminate if Vps13 primary function is in actin
cytoskeleton or membrane dynamics or it is a bridging protein.
Complementary to our findings, Lang and coworkers have re-
cently shown that Vps13 is localized at membrane contact sites
(MCS) in yeast (55). MCS are structures where two membranes are
tethered in close apposition but not fused. These junctions allow
the exchange of ions, metabolites and lipids between organelles
in response to a cell’s needs (56). Vps13^GFP, with internal GFP,
was found in endosomes and in MCS integrating the mitochon-
dria and vacuole (called vCLAMP) when cells were grown on glu-
cose medium, but in nuclear-vacuolar junctions when shifted to
glycerol medium (55). These findings were further confirmed and
extended by documenting that vps13 mutants have defects in
mitochondrial functioning and Vps13 protein, besides vCLAMP
and nuclear-vacuolar junctions, is also located in endosome-
mitochondrial junctions and through these different localizations
promotes different processes (57). It was demonstrated that
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different processes known to require functional Vps13: sporula-
tion, transport of CPY to the vacuole and the formation of some
MCS are genetically independent and can be separated by differ-
ent VPS13 mutations (57). Thus, it is possible that Vps13 carries
out several independent functions – in actin cytoskeleton organ-
ization, endosomal trafficking, sporulation, and in MCS formation
or carries one function in these different processes but requires
different domains to act in these various locations. Many of the
proteins being important for the formation and function of MCS
have been linked to other cellular processes (58–61). Thus, func-
tion of Vps13 in MCS may be linked to its ability to regulate the
actin cytoskeleton organization and protein transport at the
same time.
Beyond actin-binding ability, we have found that SHR_BD
and APT1 domains of Vps13 interact with PIPs together and in-
dependently. SHR_BD domain bound many of the PIPs tested
while the APT1 domain conferred specificity towards PI3P. The
SHR_BD domain is also presented in hVps13A and we have also
found a putative APT1 domain in this protein, suggesting that
hVps13A may also interact with specific phospholipids. These
findings added Vps13 family proteins to the superfamily of
lipid-binding proteins and supports the notion that Vps13 could
Figure 5. The level of PI3P influences the localization of Vps13-GFP. (A) Localization of Vps13-GFP in PI3P deficient vps30D and vps38D cells. Strains transformed with
plasmid bearing PTEF1-VPS13-GFP were grown in SC-leu minimal medium to log-phase and the localization of Vps13-GFP was observed by fluorescence microscopy. At
least 100 cells for each strain were observed. The percentage of cells displaying various Vps13-GFP distribution patterns, illustrated in the right-hand panel, is shown.
(B) Colocalization of Vps13-GFP and FM4-64 in vps30D strain. The vps30D strain was transformed with a plasmid encoding PTEF1-VPS13-GFP. Cells were grown in SC-leu
medium to log-phase and the localization of Vps13-GFP protein was observed by confocal microscopy. FM4-64 was used to visualize the compartments of endocytic
pathway. Scale bar, 5 mm. (C) Localization of Vps13-GFP and Snf7-RFP in vps30D strain. The SNF7-RFP vps30D strain was transformed with a plasmid encoding PTEF1-
VPS13-GFP. Cells were grown in SC-leu medium to log-phase and the localization of Snf7-RFP and Vps13-GFP proteins was observed by confocal microscopy.
1505Human Molecular Genetics, 2017, Vol. 26, No. 8 |
be able to bind membranes, including endosomal membranes
enriched in PI3P, and even tether two membranes together in
various MCSs via two lipid-binding domains. While this work
was in revision, data complementary to our data were pub-
lished which show that Vps13 contains at least two more lipid-
binding domains at the N- and C-terminus, respectively (62).
Moreover, the authors predicted the presence of PI3P-binding
domain in the central part of the Vps13 protein (62) and that is
in agreement with our findings.
PI3P seems also to regulate Vps13 localization, since we have
observed that a decreased level of endosomal PI3P in vps30D
cells markedly altered the localization of the Vps13 protein; it
was accumulated in a large perivacuolar membrane compart-
ment of endocytic origin reminiscent to the class E compart-
ment observed when vacuolar sorting is blocked (63) but such a
compartment is normally not observed in vps30D (64). This com-
partment may also be an insoluble protein deposit where ab-
normal, aggregated or overproduced proteins are sequestered
(32,65) and where Vps13-GFP may be held when endocytic traffic
is disturbed. It was observed previously that decreased level of
PI3P leads to diffusion of Vps5-GFP and Vps17-GFP, subunits of
the retromer complex, and GFP-Vps27, an ESCRT-0 protein,
from the endosome to cytoplasm (24,25). Vps13 behaved in the
opposite way, as PI3P would be required for its release from
endosome. However, in contrast to our data showing that
VPS13-GFP is fully functional in the actin cytoskeleton and ves-
icular transport, recent reports indicate that Vps13-GFP (tagged
at the C terminus) is inactive in MCS formation (55,57), thus we
cannot exclude that the Vps13-GFP localization, we observed in
mutants, at least in part results from this inability.
Modeling of I2771R substitution found in APT1 domain of
hVps13A in ChAc patient (I2749R in yeast) showed that it greatly
affects its function. Despite the similar level of mutant Vps13-
I2749R-GFP to that of wild type one, it was unable to comple-
ment vps13D defects, such as depolarization of actin cytoskel-
eton, secretion of CPY, hypersensitivity to canavanine and
delay in Sna3-GFP degradation, indicating a loss of function.
This mutant phenotype was linked with diminished lipid-
binding ability, specifically to PI3P, and a change in endosomal
localization when the endosomal level of PI3P is low. Another
four missense mutations found in ChAc patients were recently
modeled in yeast cells and respective mutants, vps13-L66P,
vps13-C89K, vps13-L1107P and VPS13-Y2702C, were tested for
sporulation, CPY sorting and synthetic lethality with mmm1D
(57), an ERMES mutant (66). VPS13-Y2702C did not show defects
of these processes, all others show efficient sporulation but
were synthetically lethal with mmm1D allele. The vps13-L1107P
mutant additionally displayed a CPY sorting defect (57). None of
these mutation caused amino acid substitutions in the APT1 do-
main of Vps13. Thus, our analysis is complementary to these
findings and shows that for proper transport of CPY, in addition
to leucine 1107, isoleucine 2749 in the APT1 domain is required.
Therefore, two distinct domains of Vps13 must cooperate for
this one function. Our recent analysis shows that vps13-I2749R
mutation also causes defect in sporulation and lethality with
mmm1D (Supplementary Material, Tables S1 and S2) showing
again for cooperation of several domains in one process. Based
on our and other results, we hypothesize that the I2771R muta-
tion may alter PI3P binding by APT1 of hVps13A and the inter-
action of hVps13A with PI3P-enriched membranes, and this
interferes with hVps13A trafficking and formation of MCS. That
leads to the observed transport and actin cytoskeleton defects
in human cells and could be one of the mechanisms of ChAc
pathogenesis.
Our and other studies show that it is possible in yeast to suc-
cessfully mimic hVPS13A mutations found in ChAc patients and
this model can provide us useful information about function of
Vps13 protein and possible mechanism of the disease. Yeast
ChAc model is also potentially useful for high-throughput
chemical screen to select possible drugs.
Materials and Methods
Strains, media and growth conditions
E. coli strain DH5a was used for plasmid propagation. The yeast
S. cerevisiae strains were used in this study: BY4741 (MATa
his3D1 leu2D0 met15D0 ura3D0), BY4741 vps13D (MATa his3D1
leu2D0, met15D0 ura3D0 vps13D::KanMX), BY4741 vps30D (MATa
his3D1 leu2D0, met15D0 ura3D0 vps30D::KanMX), BY4741 vps38D
(MATa his3D1 leu2D0, met15D0 ura3D0 vps38D::KanMX), BY4741
atg14D (MATa his3D1 leu2D0, met15D0 ura3D0 atg14D::KanMX)
(Open Biosystem) and KAY687 (MATa SNF7-RFP::KanMX his3D1
leu2D0 lys2D0 ura3D0) (14).
To construct strain SNF7-RFP vps30D, first KanMX at SNF7 locus
was replaced by HIS3 in KAY687 and next vps30D::KanMX casette
was introduced and the resulting strain was named KJK173.
Yeast cells were grown at 28 C in liquid YPD medium (1%
yeast extract, 2% bactopeptone, 2% glucose) or in synthetic com-
plete medium SC (0.67% yeast nitrogen base without amino
acids, 2% glucose, 0.2% complete supplement mixture -ade-his-
leu-trp-ura) with desired supplements (uracil and amino acids)
if selection for plasmid maintenance was required. For growth
test, the cells were grown overnight in SC-leu medium, pelleted
and resuspended to OD600¼1 in synthetic minimal medium SD
(0.67% yeast nitrogen base without amino acids, 2% glucose)
with required supplements and 1:4 serial dilutions were pre-
pared. Aliquots of each dilution were spotted on SD-leu min-
imal plates with required supplements and SD-leu-arg
supplemented with 1-3 mg ml 1or without L-canavanine and
then incubated at 28 C for 4 days.
Plasmids and plasmid construction
Plasmids used in this study are listed in Table 1. Plasmid
pRS415-VPS13 was constructed by gap-repair in yeast cells and
contains VPS13 open reading frame (ORF) under the transcrip-
tional control of native promoter and terminator sequences
(chromosome XII coordinates: 64064 - 53920). For C-terminal
GFP tagging of Vps13, the pUG35-VPS13 plasmids was produced
by amplification of two fragments of the VPS13 ORF by PCR
using pRS415-VPS13 as a template and primers providing re-
striction sites (a 700-bp 5’-end fragment flanked by XmaI and
EcoRI sites and the 400-bp 3’-end one flanked by EcoRI and
XhoI sites and devoid of the STOP codon), ligation of both frag-
ments into XmaI/XhoI-linearized pUG35 vector and subsequent
transfer of the 8361-bp BclI-BclI central part of VPS13 from
pRS415-VPS13. The orientation of the BclI-BclI fragment was
checked by restriction analysis. Plasmids p415-PADH1-VPS13-
GFP, p415-PTEF1-VPS13-GFP and p415-PGPD-VPS13-GFP were ob-
tained by subcloning of the VPS13-GFP coding sequence with
the CYC1 terminator as a Cfr9I-Eco52I fragment from pUG35-
VPS13 into p415-PADH1, -PTEF1 and -PGPD vectors (36).
The I2749R (Att>Aga) mutation (numbering according to
yeast Vps13 aa sequence, corresponds to human hVps13A pos-
ition 2771) was introduced by site directed mutagenesis into
VPS13 fragment (bp 9221 - 8656) which was PCR-amplified with
flanking PstI and HindIII restriction sites and cloned into
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pBluescript SKII giving pBluescript-vps13-I2749R. Two silent
mutations, E2745E (GAg>GAa) and F2747F (TTc>TTt), were
also introduced to generate additional PdmI and AsuII sites and
to destroy one of the BglII sites, enabling simple confirmation of
the presence of the mutated region by restriction analysis. The
mutations were subsequently introduced into full-length VPS13
by substitution of the 1545-bp BbvCI-AjiI DNA fragment of
pRS415-VPS13 or p415-PTEF1-VPS13-GFP with the corresponding
one from pBluescript-vps13-I2749R.
The human hVPS13A ORF was PCR-amplified without the
STOP codon using cDNA (synthesized on mRNA isolated from
human blood cells) as a template and primers with flanking
Cfr9I and SalI restriction sites. The obtained product was di-
gested with Cfr9I and SalI and ligated into Cfr9I/SalI-linearized
pUG35. A fragment containing hVPS13A-GFP-TCYC1 was excised
with Cfr9I and Eco52I from pUG35-hVPS13A plasmid and subcl-
oned into p415-PADH1, -PTEF1 and -PGPD vectors in the same sites.
For production of truncated Vps13 variants in E. coli, appropri-
ate constructs encoding N-terminally GST-tagged proteins were
created. The pKF463 vector, encoding the GST tag alone, was
used as a control. It is based on the pGEX-4T-1 backbone and
carries a STOP codon directly downstream of the encoded TEV
protease cleavage site (32). Appropriate VPS13 fragments were
PCR-amplified on genomic DNA of the S288C strain and cloned
into pKF463. The vps13-APT1 (aa S2492-P2844) and vps13-SHR_BD
-APT1 (aa S2158-P2844) fragments encoding the APT1 and the
SHR_BD-APT1 domains were cloned, respectively, as 1077-bp or
2079-bp Esp3I-Esp3I fragments into 4978-bp AarI/SalI- or 4972-bp
AarI/XhoI-digested pKF463 yielding pKF482 and pKF483, respect-
ively. The SHR_BD-coding sequence was cloned as a 1308-bp
Esp3I-Esp3I fragment (TEV_c.s.-vps13(S2158-K2575)-2STOP) into
4954-bp BamHI/XhoI-digested pKF463 giving pKF490. The I2749R
mutation was introduced into vps13-SHR_BD-APT1 sequence by
substitution of the 677-bp NdeI-AjiI fragment of pKF483 with the
equivalent one from pBluescript-vps13-I2749R.
Plasmid pDK106 encoding GST-Fab1-(FYVE) contains frag-
ment of yeast FAB1 gene encoding FYVE domain (aa S233-D303)
on the pKF463 backbone.
Western blot analysis
Yeast cells were grown at 28C on SC-leu or SC-ura-leu to the
log-phase. Protein extracts were prepared after disrupting cells
with glass beads in 2x electrophoresis sample buffer (120 mM
Tris-HCl pH 6.8, 2% SDS, 20% glycerol, 0.04% bromophenol blue,
10% b-mercaptoethanol) or in IP buffer (50 mM Tris-HCl pH 8.0,
0.2 mM CaCl2, 150 mM NaCl, 2% Triton X-100, 1 mM PMSF,
Inhibitor protease cocktail (Sigma-Aldrich, Saint Louis, MI, USA)).
Samples were analyzed by standard SDS-PAGE followed by west-
ern blotting using mouse monoclonal anti-GFP (Roche, Basel,
Switzerland) or anti-actin (Millipore, Darmstadt, Germany) anti-
bodies; secondary anti-mouse IgG horseradish peroxidase (HRP)-
conjugated antibody (Dako, Glostrup, Denmark) and signal de-
tection by enhanced chemiluminescence (Millipore).
Secretion of CPY
To test the secretion of CPY the cells were grown overnight at
28 C and then diluted to OD600¼1. Ten microliters of each cul-
ture was dropped on nitrocellulose membrane on an SC-leu
Table 1. Plasmids used in this study
Plasmid Source or reference
p415-PADH1 (36)
p415-PADH1-hVPS13A This study
p415-PADH1-hVPS13A-GFP This study
p415-PADH1-VPS13-GFP This study
p415-PGPD (36)
p415-PGPD-hVPS13A This study
p415-PGPD-hVPS13A-GFP This study
p415-PGPD-VPS13-GFP This study
p415-PTEF1 (36)
p415-PTEF1-hVPS13A This study
p415-PTEF1-hVPS13A-GFP This study
p415-PTEF1-VPS13-GFP This study
p415-PTEF1-vps13-I2749R-GFP This study
p416-SNA3-GFP (37)
pBluescript SKII Agilent Technologies, Santa Clara, CA, USA
pBluescript-vps13-I2749R This study
pDK106 (Ptac-GSTtag-Thrombin_c.s.-TEV_c.s.- fab1-(S233-D303)) D. Kolakowski, IBB PAS
pKF463 (Ptac-GSTtag-Thrombin_c.s.-TEV_c.s.- 2STOP) (32)
pKF482 (Ptac-GSTtag-Thrombin_c.s.-TEV_c.s.- vps13-(S2492-P2844)) This study
pKF483 (Ptac-GSTtag-Thrombin_c.s.-TEV_c.s.- vps13-(S2158-P2844)) This study
pKF490 (Ptac-GSTtag-Thrombin_c.s.-TEV_c.s.- vps13-(S2158-K2575)) This study
pKF492 (Ptac-GSTtag-Thrombin_c.s.-TEV_c.s.- vps13-(S2158-P2844)-I2749R) This study
pRS415 (68)
pRS415-VPS13 This study
pRS415-vps13-I2749RC This study
pUG35 J.H. Hegemann, University of Du¨sseldorf
pUG35-hVPS13A This study
pUG35-VPS13 This study
All plasmids confer resistance to 100 mg ml 1 ampicillin; c.s – cleavage site.
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plate and incubated for 14–16 h at 28 C. Then cells were washed
off the membrane and the secreted CPY was detected with an
anti-CPY antibody (Thermo Fisher Scientific, Waltham, MA,
USA).
Immunoprecipitation
Immunoprecipitation was performed using GFP-Trap
(ChromoTek, Martinsried, Germany) according to the manufac-
turer protocol. The vps13D strains bearing empty plasmid or
plasmids carrying GFP, VPS13-GFP or vps13-I2749R-GFP under the
TEF1 promoter were grown in SC-leu medium to log-phase.
About 50 OD600 of culture was collected and cells were disrupted
using glass beads in CoIP buffer (50 mM HEPES, pH 7.5, 100 mM
NaCl, 1 mM MgCl2, 0.5% Triton X-100, 1 mM PMSF; Inhibitor pro-
tease cocktail (Sigma-Aldrich)). To remove unbroken cells and
cell debris, samples were centrifuged at 10 000 g. The super-
natant was incubated with GFP-Trap (ChromoTek) for 2 h at
4 C. After incubation beads were washed five times with 50 mM
HEPES pH 7.5. The samples were analyzed by SDS-PAGE fol-
lowed by western blotting using mouse monoclonal anti-GFP
(Roche) and mouse monoclonal anti-actin (Millipore)
antibodies.
Fluorescence and confocal microscopy
To observe membranes, yeast cells were grown to log-phase in
SC-leu medium, collected, resuspended in ice-cold YPD medium
supplemented with 40 mM FM4-64 (Thermo Fisher Scientific),
and incubated for 30 min on ice. The cells were then washed
with ice-cold YPD medium, incubated for 60 min at 30 C and
then the sodium azide and fluoride were added.
For actin cytoskeleton staining, cells were grown to log-
phase, fixed for 2 h by the addition of formaldehyde to 3.7%,
stained with 546 Alexa Fluor-conjugated phalloidin (Thermo
Fisher Scientific) and washed.
To analyze localization of Vps13-GFP or Vps13-I2749R-GFP,
the wild type, vps30D, vps38D, atg14D or SNF7-RFP vps30D cells
were transformed with respective plasmids, grown, and were
observed by fluorescence or confocal microscopy, as indicated.
Cells were viewed with an Eclipse E800 fluorescence micro-
scope (Nikon, Tokyo, Japan) equipped with a DS-5Mc camera
(Nikon). Images were collected using Lucia General 5.1 software
(Laboratory Imaging Ltd., Praha, Czech Republic). The same
fields were viewed by differential interference contrast (DIC)
optics. Confocal imaging was perform using confocal laser scan-
ning microscope EZ-C1 Eclipse TE2000-E (Nikon) equipped with
a Plan Apo 60objective (NA 1.4). Images were collected with
EZ-C1 confocal V. 3.6 program (Nikon). Images were processed
with EC1 Viewer 3.6 and Adobe Photoshop 8.0.
Purification of Vps13 fragments and determination of
their binding to lipids
Truncated variants of Vps13 were expressed as N-terminally
GST-tagged recombinant proteins in E. coli BL21(DE3) strain
propagated at 28 C in 2 LB medium supplemented with
50 mM HEPES pH 7.4 and 100 mg ml 1 carbenicillin (Sigma-
Aldrich) for plasmid maintenance. Expression was induced with
0.2 mM IPTG for 4-6 h. Then cells were pelleted, resuspended in
phosphate-buffered saline (PBS) supplemented with protease
inhibitor cocktail (complete Mini, EDTA-free; Roche) and lysed
by sonication. The homogenate was clarified by incubation with
benzonase endonuclease at 5-10 U ml 1 (Merck Millipore) fol-
lowed by centrifugation at 20 000 g for 15 min at 4 C. The
supernatant was supplemented with 2% Triton X-100, 1 mM
EDTA and 5 mM DL-dithiothreitol (DTT), and incubated with
glutathione magnetic beads (Thermo Scientific) for 2-3 h at 4 C.
After washing steps, the bound proteins were eluted with
25 mM reduced glutathione in elution buffer (100 mM TrisCl pH
8.0, 150 mM NaCl, 2 mM EDTA, 2 mM DTT, 0.1% Tween-20) and
the purity of eluted proteins was analyzed by SDS-PAGE.
Identification of lipids interacting with a given protein was
done by an overlay assay. A membrane containing lipids (PIP
Strips; Echelon Biosciences Inc., Salt Lake City, UT, USA) was
blocked with 3% fatty acid-free BSA (Sigma-Aldrich) in PBS-T
(PBS, 0.1% Tween-20) and then incubated overnight at 4 C in
blocking buffer with 0.5-1 mg ml 1 of particular protein or GST
alone as a negative control. Bound proteins were detected with
anti-GST HRP-conjugated antibodies (Sigma-Aldrich).
Liposome-binding assays
Liposomal assays were carried out using synthetic biotin-
tagged PolyPIPosomes containing 5% (w/w) individual phos-
phoinositides (Echelon Biosciences Inc.). Crude E. coli extracts
containing GST-Vps13-(SHR_BD-APT1), GST-Vps13-I2749R-
(SHR_BD-APT1) or GST-Fab1-(FYVE) domain, as a positive con-
trol, were incubated with 10 ml of liposome mixtures in 1 ml re-
action buffer (50 mM HEPES, pH 7.5, 100 mM NaCl, and 1 mM
MgCl2) for 20 min at room temperature. Next, 50 ll of Dynabeads
MyOne Streptavidin T1 (Invitrogen) were added to pull down
the lipid–protein mixtures for 1 h at 4 C. Following 5 washes
with 0.5 ml reaction buffer, the beads were mixed with 2 sam-
ple buffer and processed for western blotting using anti-GST
antibody.
Supplementary Material
Supplementary Material is available at HMG online.
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